Literature DB >> 3612743

The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits.

J M Ketley, T J Mitchell, D C Candy, D W Burdon, J Stephen.   

Abstract

Rabbits were solidly immunised by parenteral injection of purified Clostridium difficile toxin A such that they resisted an intravenous challenge with a normally lethal dose of toxin A. Ileal and colonic loops constructed in non-immune and immune animals received challenge injections of crude culture filtrate or purified toxin A of C. difficile. Protection of ileum was manifest after sufficient initial mucosal damage resulted in release of high levels of antitoxin A into the loop lumen of immune animals. There was less fluid accumulation in ligated ileal loops of immune than of non-immune rabbits. Less protection was observed when loops were challenged with crude culture filtrate containing toxins A and B than when challenged with purified toxin A. In-vitro studies with Ussing chambers yielded no evidence for tissue-localised immunity as judged by electrical responses and histology of toxin-treated tissue from non-immune and immune animals. No differences were found in the degree of epithelial damage, or volume or composition of fluid accumulating in colonic loops of non-immune and immune rabbits challenged with toxin A or crude culture filtrate. However, in colonic loops of immune rabbits there was no overt tissue-localised haemorrhage, whereas in those of non-immune rabbits tissue-localised haemorrhage was marked. In contrast to our findings with ileal loops, fluid accumulating in colonic loops was watery and contained substantially less total protein and (in immune animals) antitoxin A.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612743     DOI: 10.1099/00222615-24-1-41

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

2.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

3.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 4.  The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Authors:  Xingmin Sun; Simon A Hirota
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

5.  Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.

Authors:  S J Ward; G Douce; D Figueiredo; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.

Authors:  S J Ward; G Douce; G Dougan; B W Wren
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 7.  The enterotoxicity of Clostridium difficile toxins.

Authors:  Xingmin Sun; Tor Savidge; Hanping Feng
Journal:  Toxins (Basel)       Date:  2010-07-14       Impact factor: 4.546

8.  The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction.

Authors:  Ashleigh Hansen; Laurie Alston; Sarah E Tulk; L Patrick Schenck; Michael E Grassie; Basmah F Alhassan; Arun Teja Veermalla; Samir Al-Bashir; Fernand-Pierre Gendron; Christophe Altier; Justin A MacDonald; Paul L Beck; Simon A Hirota
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.